from ceo12 Nov 2009 08:59
Stephen Jones, Chief Executive Officer of Syntopix, said: "We believe that SYN0126 has the potential to be a significant step forward in the management of acneic skin, a condition that affects 85% of the population at some stage during their lifetime. This study confirms that our rigorous screening programme is yielding results. We are now actively pursuing discussions with leading cosmetic and consumer healthcare companies to investigate the possibility of securing a licensing agreement for SYN0126 and are confident that the positive results from this study will lead to commercial deals in the near future."